John R. Manthei

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA
Profile Experience

John Manthei, Global Chair of the Healthcare & Life Sciences Practice, focuses his practice on regulatory matters involving the US Food and Drug Administration (FDA) for the medical device, pharmaceutical, and biotechnology industries.

Mr. Manthei’s practice includes assisting clients with all aspects of the FDA-regulated product life cycle, including, among others: 

  • Pre-market development
  • FDA product submissions
  • Development of market exclusivity strategies
  • Drafting and negotiation of both US and international clinical trial agreements
  • FDA and Federal Trade Commission (FTC) regulation of marketing and promotion of products
  • Quality System Regulation and Good Manufacturing Practice requirements (including assisting in third-party audits and drafting SOPs)
  • FDA inspections; recalls
  • FDA and DEA export and import requirements
  • Civil and criminal compliance and enforcement 

Mr. Manthei has also been involved extensively in Administrative Procedures Act litigation, including successfully challenging the Agency in Catalyst Pharmaceuticals v. FDA, Eagle Pharmaceuticals v. FDA, Pacira Pharmaceuticals v. FDA, Endo/Par Pharmaceuticals v. FDA, Genus Medical Technologies v. FDA, Sottera/NJOY v. FDA, and Commonwealth v. FDA, as well as successfully intervening to defend FDA actions on behalf of clients in Teva v. FDA, Weyth Pharmaceuticals v. FDA, and Athenex v. FDA.

Prior to joining Latham, Mr. Manthei served as Majority Counsel for the US House of Representatives’ Committee on Energy and Commerce (1998-2000). He counseled the Full Commerce Committee Chairman; the Health and Environment and Oversight and Investigations Subcommittee Chairmen; as well as the House Leadership on matters relating to the FDA and legislation concerning the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act.

Since 2000, Mr. Manthei has represented the pharmaceutical, biotechnology, and medical device industries as counsel in nearly every major FDA legislative initiative. He has also testified before Congress on several occasions involving FDA and DEA regulatory and enforcement matters.

Mr. Manthei is ranked Band 1 by Chambers USA 2022 for Healthcare: Pharmaceutical/Medical Products Regulatory - District of Columbia. He has been consistently recognized as a leading lawyer in Chambers USA (2010-2022), named a Life Sciences Industry Star by LMG Life Sciences (2012-2021), and a Leading Lawyer in the Healthcare: Life Sciences category by The Legal 500 US (2012-2022). Mr. Manthei was also inducted into the “Hall of Fame” by The Legal 500 US, a distinction shared with only four others across all legal practice areas nationwide. In addition, he was named a Life Sciences MVP by Law360 (2016) and recognized as a Trailblazer by the National Law Journal (2018). He has been repeatedly recognized by Washingtonian magazine, including as one of Washington's Best Lawyers. He currently serves as outside FDA counsel to the Medical Device Manufacturers Association (MDMA).

Mr. Manthei has authored numerous articles and has been a featured speaker and lecturer on FDA regulatory and enforcement matters at events sponsored by the Pharmaceutical Research and Manufacturers Association (PhRMA), the Biotechnology Industry Organization (BIO), AdvaMed, MDMA, BioCom, CLSA, the Food and Drug Law Institute (FDLI), the American Health Lawyers Association (AHLA), GMA, Harvard University, Stanford University, and MIT, among others. He has been quoted in CBS News, The Washington Post, CNN, USA Today, CNBC, The Boston Globe, San Francisco Chronicle, Forbes, and Business Week

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.